Core Insights - Medicus Pharma Ltd. will participate in the Longwood Miami CEO Forum, focusing on its AI-enabled drug development strategy aimed at enhancing clinical trial efficiency [1][2] - The company is actively engaged in developing innovative therapeutics, including a non-invasive treatment for basal cell skin cancer and a next-generation GnRH antagonist for prostate cancer [1][2] Company Participation and Events - Dr. Raza Bokhari, Executive Chairman & CEO, will be part of a panel titled "Accelerating the Path to Patient Care" at the Longwood Miami CEO Forum on March 12-13, 2026 [1] - The event will feature notable industry leaders and aims to foster discussions on healthcare innovation [1] Strategic Collaborations and Developments - Medicus has entered a non-binding memorandum of understanding with Helix Nanotechnologies to explore joint development opportunities in mRNA technology [1][2] - The company completed the acquisition of Antev, focusing on a new treatment for advanced prostate cancer, which may improve patient compliance and outcomes [1][2] Clinical Trials and Regulatory Approvals - The company has received regulatory approvals in the UK for its Phase 2 clinical study evaluating D-MNA for treating basal cell carcinoma [2] - Medicus has successfully enrolled 90 patients in the U.S. for the same study and anticipates an end-of-Phase 2 meeting with the FDA in the first half of 2026 [2] Future Plans and Innovations - Medicus plans to collaborate with Reliant AI Inc. to develop an AI-driven clinical data analytics platform to enhance clinical trial efficiency [2] - The company has received FDA clearance to initiate a Phase 2b dose-optimization study of Teverelix for advanced prostate cancer [2]